guest ::
| Home > Publications Database > Levels of Neurofilament Light at the Preataxic and Ataxic Stages of Spinocerebellar Ataxia Type 1 > print |
| Home > Publications Database > Levels of Neurofilament Light at the Preataxic and Ataxic Stages of Spinocerebellar Ataxia Type 1 > print |
| 001 | 164658 | ||
| 005 | 20230915090555.0 | ||
| 024 | 7 | _ | |a pmc:PMC9162044 |2 pmc |
| 024 | 7 | _ | |a 10.1212/WNL.0000000000200257 |2 doi |
| 024 | 7 | _ | |a 0028-3878 |2 ISSN |
| 024 | 7 | _ | |a 1526-632X |2 ISSN |
| 024 | 7 | _ | |a altmetric:126089582 |2 altmetric |
| 024 | 7 | _ | |a pmid:35264424 |2 pmid |
| 037 | _ | _ | |a DZNE-2022-01188 |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Wilke, Carlo |0 P:(DE-2719)2814101 |b 0 |e First author |u dzne |
| 245 | _ | _ | |a Levels of Neurofilament Light at the Preataxic and Ataxic Stages of Spinocerebellar Ataxia Type 1 |
| 260 | _ | _ | |a [S.l.] |c 2022 |b Ovid |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1655284052_27752 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a Neurofilament light (NfL) appears to be a promising fluid biomarker in repeat-expansion spinocerebellar ataxias (SCAs), with piloting studies in mixed SCA cohorts suggesting that NfL might be increased at the ataxic stage of SCA type 1 (SCA1). We here hypothesized that NfL is increased not only at the ataxic stage of SCA1, but also at its (likely most treatment-relevant) preataxic stage.Methods We assessed serum NfL (sNfL) and CSF NfL (cNfL) levels in both preataxic and ataxic SCA1, leveraging a multicentric cohort recruited at 6 European university centers, and clinical follow-up data, including actually observed (rather than only predicted) conversion to the ataxic stage. Levels of sNfL and cNfL were assessed by single-molecule array and ELISA technique, respectively.Results Forty individuals with SCA1 (23 preataxic, 17 ataxic) and 89 controls were enrolled, including 11 preataxic individuals converting to the ataxic stage. sNfL levels were increased at the preataxic (median 15.5 pg/mL [interquartile range 10.5–21.1 pg/mL]) and ataxic stage (31.6 pg/mL [26.2–37.7 pg/mL]) compared to controls (6.0 pg/mL [4.7–8.6 pg/mL]), yielding high age-corrected effect sizes (preataxic: r = 0.62, ataxic: r = 0.63). sNfL increases were paralleled by increases of cNfL at both the preataxic and ataxic stage. In preataxic individuals, sNfL levels increased with proximity to predicted ataxia onset, with significant sNfL elevations already 5 years before onset, and confirmed in preataxic individuals with actually observed ataxia onset. sNfL increases were detected already in preataxic individuals with SCA1 without volumetric atrophy of cerebellum or pons, suggesting that sNfL might be more sensitive to early preataxic neurodegeneration than the currently known most change-sensitive regions in volumetric MRI. Using longitudinal sNfL measurements, we estimated sample sizes for clinical trials with the reduction of sNfL as the endpoint.Discussion sNfL levels might provide easily accessible peripheral biomarkers in both preataxic and ataxic SCA1, allowing stratification of preataxic individuals regarding proximity to onset, early detection of neurodegeneration even before volumetric MRI alterations, and potentially capture of treatment response in clinical trials.Trial Registration Information ClinicalTrials.gov Identifier: NCT01037777.Classification of Evidence This study provides Class III evidence that NfL levels are increased in both ataxic and preataxic SCA1 and are associated with ataxia onset. |
| 536 | _ | _ | |a 353 - Clinical and Health Care Research (POF4-353) |0 G:(DE-HGF)POF4-353 |c POF4-353 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, Journals: pub.dzne.de |
| 650 | _ | 2 | |a Atrophy: pathology |2 MeSH |
| 650 | _ | 2 | |a Biomarkers |2 MeSH |
| 650 | _ | 2 | |a Cerebellar Ataxia: pathology |2 MeSH |
| 650 | _ | 2 | |a Cerebellum: pathology |2 MeSH |
| 650 | _ | 2 | |a Humans |2 MeSH |
| 650 | _ | 2 | |a Intermediate Filaments |2 MeSH |
| 650 | _ | 2 | |a Neurofilament Proteins |2 MeSH |
| 650 | _ | 2 | |a Spinocerebellar Ataxias: diagnosis |2 MeSH |
| 700 | 1 | _ | |a Mengel, David |0 P:(DE-2719)9000375 |b 1 |u dzne |
| 700 | 1 | _ | |a Schöls, Ludger |0 P:(DE-2719)2810795 |b 2 |u dzne |
| 700 | 1 | _ | |a Hengel, Holger |0 P:(DE-2719)2811940 |b 3 |u dzne |
| 700 | 1 | _ | |a Rakowicz, Maria |b 4 |
| 700 | 1 | _ | |a Klockgether, Thomas |0 P:(DE-2719)2810314 |b 5 |u dzne |
| 700 | 1 | _ | |a Dürr, Alexandra |0 P:(DE-2719)9000429 |b 6 |u dzne |
| 700 | 1 | _ | |a Filla, Alessandro |b 7 |
| 700 | 1 | _ | |a Melegh, Bela |b 8 |
| 700 | 1 | _ | |a Schüle, Rebecca |0 P:(DE-2719)2812018 |b 9 |u dzne |
| 700 | 1 | _ | |a Reetz, Kathrin |b 10 |
| 700 | 1 | _ | |a Jacobi, Heike |0 P:(DE-2719)2811564 |b 11 |u dzne |
| 700 | 1 | _ | |a Synofzik, Matthis |0 P:(DE-2719)2811275 |b 12 |e Last author |u dzne |
| 773 | _ | _ | |a 10.1212/WNL.0000000000200257 |g Vol. 98, no. 20, p. e1985 - e1996 |0 PERI:(DE-600)1491874-2 |n 20 |p e1985 - e1996 |t Neurology |v 98 |y 2022 |x 0028-3878 |
| 909 | C | O | |o oai:pub.dzne.de:164658 |p VDB |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 0 |6 P:(DE-2719)2814101 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 1 |6 P:(DE-2719)9000375 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 2 |6 P:(DE-2719)2810795 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 3 |6 P:(DE-2719)2811940 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 5 |6 P:(DE-2719)2810314 |
| 910 | 1 | _ | |a External Institute |0 I:(DE-HGF)0 |k Extern |b 6 |6 P:(DE-2719)9000429 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 9 |6 P:(DE-2719)2812018 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 11 |6 P:(DE-2719)2811564 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 12 |6 P:(DE-2719)2811275 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Neurodegenerative Diseases |1 G:(DE-HGF)POF4-350 |0 G:(DE-HGF)POF4-353 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Clinical and Health Care Research |x 0 |
| 914 | 1 | _ | |y 2022 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2021-01-27 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2021-01-27 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2021-01-27 |
| 915 | _ | _ | |a Allianz-Lizenz |0 StatID:(DE-HGF)0410 |2 StatID |d 2022-11-12 |w ger |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2022-11-12 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2022-11-12 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2022-11-12 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2022-11-12 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2022-11-12 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2022-11-12 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b NEUROLOGY : 2021 |d 2022-11-12 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2022-11-12 |
| 915 | _ | _ | |a IF >= 10 |0 StatID:(DE-HGF)9910 |2 StatID |b NEUROLOGY : 2021 |d 2022-11-12 |
| 920 | 1 | _ | |0 I:(DE-2719)1240005 |k Core ICRU |l Core ICRU |x 0 |
| 920 | 1 | _ | |0 I:(DE-2719)1210000 |k AG Gasser 1 |l Parkinson Genetics |x 1 |
| 920 | 1 | _ | |0 I:(DE-2719)1011001 |k AG Klockgether |l Clinical Research- coordination |x 2 |
| 920 | 1 | _ | |0 I:(DE-2719)5000024 |k AG Maetzler |l Functional Neurogeriatrics |x 3 |
| 920 | 1 | _ | |0 I:(DE-2719)1011101 |k Patient studies, Bonn |l Patient studies |x 4 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-2719)1240005 |
| 980 | _ | _ | |a I:(DE-2719)1210000 |
| 980 | _ | _ | |a I:(DE-2719)1011001 |
| 980 | _ | _ | |a I:(DE-2719)5000024 |
| 980 | _ | _ | |a I:(DE-2719)1011101 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|